We assessed whether MAPK and/or PI3K/Akt pathways were modulated by co-targeting of STYK1 and EGFR in NSCLC cells and found that while afatinib inhibited the activation of ERK and Akt, phosphorylated (active) levels of these kinases were not affected by STYK1 knockdown alone, or further reduced by the combination of STYK1 siRNA and afatinib, compared to afatinib alone (Fig. 3G & Suppl. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.